Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysis
Metrics: PDF 1159 views | HTML 1012 views | ?
Yu-Pei Chen1,*, Wen-Na Zhang1,*, Lei Chen1,*, Ling-Long Tang1, Yan-Ping Mao1, Wen-Fei Li1, Xu Liu1, Guan-Qun Zhou1, Ying Sun1, Tie-Bang Kang1, Mu-Sheng Zeng1, Na Liu1, Jun Ma1
1Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, People’s Republic of China
*These authors have contributed equally to this work
Na Liu, e-mail: firstname.lastname@example.org
Jun Ma, e-mail: email@example.com
Keywords: LMP1, EBV, cancer, survival, meta-analysis
Received: May 20, 2015 Accepted: August 07, 2015 Published: August 18, 2015
Latent membrane protein 1 (LMP1) is identified as the main transforming oncoprotein of Epstein-Barr virus (EBV). LMP1 is frequently expressed in a variety of EBV-associated cancers, including nasopharyngeal carcinoma (NPC), non-Hodgkin lymphoma (NHL), Hodgkin disease (HD), and gastric cancer (GC). However, due to conflicting results, the prognostic value of LMP1 expression on clinical outcomes in EBV-associated cancers remains unclear. We performed a meta-analysis on 32 studies with a total of 3752 patients to explore the association between LMP1 expression and overall survival (OS) in EBV-associated cancers. Overall, LMP1 expression was significantly associated with poorer OS (hazard ratio, HR = 1.51, 95% confidence interval, CI, 1.13–2.03), irrespective of cancer type. Further analyses showed that LMP1 expression correlated with poorer OS in NPC (HR = 2.48, 95% CI, 1.77–3.47) and NHL patients (HR = 1.83, 95% CI, 1.07–3.15), but not in HD patients (HR = 0.98, 95% CI, 0.60–1.62) or GC patients (HR = 0.70, 95% CI, 0.44–1.12). Subgroup analyses indicated that the age and geographical factors seemed to have an effect on the clinical outcomes of HD patients with positive LMP1 expression. In conclusion, LMP1 expression can be used as a prognostic biomarker in NPC, NHL, and certain HD patients. This data suggests that novel therapies targeting LMP1 may improve clinical outcomes for EBV-associated cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.